These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15795884)

  • 1. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy.
    Silber JH
    Pediatr Blood Cancer; 2005 Jun; 44(7):607-13. PubMed ID: 15795884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-induced cardiomyopathy.
    Simmons A; Vacek JL; Meyers D
    Postgrad Med; 2008 Nov; 120(4):67-72. PubMed ID: 19020367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
    Silber JH; Cnaan A; Clark BJ; Paridon SM; Chin AJ; Rychik J; Hogarty AN; Cohen MI; Barber G; Rutkowsky M; Kimball TR; Delaat C; Steinherz LJ; Zhao H; Tartaglione MR
    Am Heart J; 2001 Oct; 142(4):577-85. PubMed ID: 11579345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardioprotection in women with neoplastic disease].
    Cardinale D; Colombo A; Bacchiani G
    G Ital Cardiol (Rome); 2012 Jun; 13(6):461-8. PubMed ID: 22622126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics].
    Mladosievicová B
    Ceska Slov Farm; 2004 Mar; 53(2):55-60. PubMed ID: 15095572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anthracycline-induced cardiomyopathy].
    Roul G; Cohen C; Lieber A
    Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
    Conklin KA
    Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention.
    Adams MJ; Lipshultz SE
    Pediatr Blood Cancer; 2005 Jun; 44(7):600-6. PubMed ID: 15856486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J; Wasserheit C
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
    Kobza C
    Clin J Oncol Nurs; 2021 Jun; 25(3):259-266. PubMed ID: 34019025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapeutics-induced heart failure].
    Paulides M; Wojnowski L
    Med Klin (Munich); 2007 Jul; 102(7):574-8. PubMed ID: 17634876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anthracyclines and the heart].
    Mazzarello GP; Morra L
    Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology of late-onset anthracycline cardiomyopathy.
    Bernaba BN; Chan JB; Lai CK; Fishbein MC
    Cardiovasc Pathol; 2010; 19(5):308-11. PubMed ID: 19747852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?
    Granger CB
    Circulation; 2006 Dec; 114(23):2432-3. PubMed ID: 17146002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.